106 related articles for article (PubMed ID: 26926424)
1. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the Mdm2-p53 pathway by the ubiquitin E3 ligase MARCH7.
Zhao K; Yang Y; Zhang G; Wang C; Wang D; Wu M; Mei Y
EMBO Rep; 2018 Feb; 19(2):305-319. PubMed ID: 29295817
[TBL] [Abstract][Full Text] [Related]
3. F-box protein FBXO31 directs degradation of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress.
Malonia SK; Dutta P; Santra MK; Green MR
Proc Natl Acad Sci U S A; 2015 Jul; 112(28):8632-7. PubMed ID: 26124108
[TBL] [Abstract][Full Text] [Related]
4. Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction.
Inuzuka H; Fukushima H; Shaik S; Wei W
Oncotarget; 2010 Nov; 1(7):685-690. PubMed ID: 21317463
[TBL] [Abstract][Full Text] [Related]
5. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development.
Xie X; Wang X; Liao W; Fei R; Wu N; Cong X; Chen Q; Wei L; Wang Y; Chen H
J Exp Clin Cancer Res; 2018 Feb; 37(1):28. PubMed ID: 29439719
[TBL] [Abstract][Full Text] [Related]
6. RNF12 Promotes Glioblastoma Malignant Proliferation via Destructing RB1 and Regulating MAPK Pathway.
Sun E; Zhang P
J Healthc Eng; 2021; 2021():4711232. PubMed ID: 34900190
[TBL] [Abstract][Full Text] [Related]
7. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
8. FOXO1 promotes cancer cell growth through MDM2-mediated p53 degradation.
Tomiyasu H; Habara M; Hanaki S; Sato Y; Miki Y; Shimada M
J Biol Chem; 2024 Apr; 300(4):107209. PubMed ID: 38519029
[TBL] [Abstract][Full Text] [Related]
9. Tau protein binds to the P53 E3 ubiquitin ligase MDM2.
Sola M; Rendon-Angel A; Rojo Martinez V; Sgrignani J; Magrin C; Piovesana E; Cavalli A; Paganetti P; Papin S
Sci Rep; 2023 Jun; 13(1):10208. PubMed ID: 37353565
[TBL] [Abstract][Full Text] [Related]
10. RNF12 X-Linked Intellectual Disability Mutations Disrupt E3 Ligase Activity and Neural Differentiation.
Bustos F; Segarra-Fas A; Chaugule VK; Brandenburg L; Branigan E; Toth R; Macartney T; Knebel A; Hay RT; Walden H; Findlay GM
Cell Rep; 2018 May; 23(6):1599-1611. PubMed ID: 29742418
[TBL] [Abstract][Full Text] [Related]
11. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.
Wienken M; Dickmanns A; Nemajerova A; Kramer D; Najafova Z; Weiss M; Karpiuk O; Kassem M; Zhang Y; Lozano G; Johnsen SA; Moll UM; Zhang X; Dobbelstein M
Mol Cell; 2016 Jan; 61(1):68-83. PubMed ID: 26748827
[TBL] [Abstract][Full Text] [Related]
12. Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection.
Pizzorno A; Dubois J; Machado D; Cartet G; Traversier A; Julien T; Lina B; Bourdon JC; Rosa-Calatrava M; Terrier O
Sci Rep; 2018 Feb; 8(1):3746. PubMed ID: 29487367
[TBL] [Abstract][Full Text] [Related]
13. EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction.
Zhao J; Blayney A; Liu X; Gandy L; Jin W; Yan L; Ha JH; Canning AJ; Connelly M; Yang C; Liu X; Xiao Y; Cosgrove MS; Solmaz SR; Zhang Y; Ban D; Chen J; Loh SN; Wang C
Nat Commun; 2021 Feb; 12(1):986. PubMed ID: 33579943
[TBL] [Abstract][Full Text] [Related]
14. Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein.
Mukherjee N; Bhunia D; Garai PK; Mondal P; Barman S; Ghosh S
J Pept Sci; 2024 Jan; 30(1):e3535. PubMed ID: 37580909
[TBL] [Abstract][Full Text] [Related]
15. Chromatin targeting of the RNF12/RLIM E3 ubiquitin ligase controls transcriptional responses.
Espejo-Serrano C; Aitken C; Tan BF; May DG; Chrisopulos RJ; Roux KJ; Demmers JA; Mackintosh SG; Gribnau J; Bustos F; Gontan C; Findlay GM
Life Sci Alliance; 2024 Mar; 7(3):. PubMed ID: 38199845
[TBL] [Abstract][Full Text] [Related]
16. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries.
Wang B; Liu J; Tandon I; Wu S; Teng P; Liao J; Tang W
Eur J Med Chem; 2021 Jul; 219():113425. PubMed ID: 33862513
[TBL] [Abstract][Full Text] [Related]
17. Tripartite motif-containing protein 26 promotes colorectal cancer growth by inactivating p53.
Lu H; Tan Z; Ko H; Naji P; Zhu R; Wang J; Huang S; Zhang YW; Zeng S
Res Sq; 2024 Jan; ():. PubMed ID: 38260302
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin E3 ligase MDM2 induces chemoresistance in colorectal cancer by degradation of ING3.
Zhang L; Zhu D; Jiang J; Min Z; Fa Z
Carcinogenesis; 2023 Oct; 44(7):562-575. PubMed ID: 37279970
[TBL] [Abstract][Full Text] [Related]
19. TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression.
Zhang Y; Huang Z; Li K; Xie G; Feng Y; Wang Z; Li N; Liu R; Ding Y; Wang J; Yang J; Jia Z
J Exp Clin Cancer Res; 2024 Jan; 43(1):16. PubMed ID: 38200609
[TBL] [Abstract][Full Text] [Related]
20. USP47 Promotes Tumorigenesis by Negative Regulation of p53 through Deubiquitinating Ribosomal Protein S2.
Cho J; Park J; Shin SC; Jang M; Kim JH; Kim EE; Song EJ
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32370049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
